Related Experiment Videos
Thymidine labeling index in breast tumors
1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
The Japanese Journal of Surgery
|March 1, 1990
Summary
Primary tumor proliferative activity, measured by thymidine labeling index (TLI), is higher in breast cancer patients. Premenopausal women without lymph node metastasis and high TLI may benefit from adjuvant chemotherapy.
Area of Science:
- Oncology
- Biomedical Research
Background:
- Tumor proliferative activity is a key factor in breast cancer progression.
- Understanding factors influencing proliferative activity is crucial for treatment stratification.
Purpose of the Study:
- To analyze the relationship between primary tumor proliferative activity and clinical/pathologic characteristics in breast disease.
- To investigate the influence of menopausal status on tumor proliferation.
Main Methods:
- Assessed thymidine labeling index (TLI) in 32 patients with malignant or benign breast disease.
- Correlated TLI with tumor size, lymph node metastasis, and nuclear grade.
- Examined TLI differences based on menopausal status.
Main Results:
- Significantly higher median TLI in cancer patients (3.48%) vs. benign disease patients (1.02%).
- TLI did not correlate with tumor size, lymph node metastasis, or nuclear grade in breast cancer patients.
- Premenopausal patients without lymph node metastasis had significantly higher TLI (5.10%) than postmenopausal patients (2.28%).
Conclusions:
- Elevated TLI indicates higher proliferation in malignant breast disease.
- Menopausal status impacts tumor proliferation, particularly in node-negative breast cancer patients.
- Premenopausal, node-negative patients with high TLI may be candidates for adjuvant chemotherapy.